Poll: What do you think of PMOS, the new name for PCOS?

The American College of Obstetricians and Gynecologists announced a name change for polycystic ovary syndrome, renaming it to PMOS (polycystic morphology ovary syndrome). The shift reflects growing recognition that the condition affects far more than reproductive health alone.

PCOS impacts approximately 1 in 10 women of reproductive age worldwide, making it one of the most common endocrine disorders. The condition causes irregular menstrual cycles, elevated androgens, and characteristic ovarian changes visible on ultrasound. However, it frequently presents with metabolic complications including insulin resistance, weight gain, and increased type 2 diabetes risk.

The name change addresses long-standing criticism from patients and clinicians alike. The old name emphasized ovarian cysts, which some women with PCOS never develop. This mislabeling delayed diagnoses and minimized the systemic nature of the disorder. The new terminology removes "cystic" language that proved misleading while keeping "morphology" to acknowledge the structural ovarian changes that remain diagnostically relevant.

The renaming carries practical implications. Better naming conventions typically improve clinical recognition and earlier intervention. Women with undiagnosed PCOS often struggle for years before receiving treatment for insulin resistance and cardiovascular risk factors. Clearer naming may help patients recognize symptoms and seek appropriate care sooner.

However, transitioning across medical literature, patient communities, and clinical practice takes time. Decades of accumulated research under the PCOS acronym means the new terminology must coexist with the old one during a lengthy transition period. Insurance coding systems and patient advocacy organizations will need updates to ensure consistent adoption.

Endocrinologists and reproductive specialists support the change as scientifically more accurate. The condition's complexity demands recognition that it extends beyond ovarian pathology to metabolic, cardiovascular, and psychological domains. PMOS better captures